Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry

Adenocarcinomas of lower oesophagus, gastro‐oesophageal junction and cardia in humans are highly invasive tumours with poor prognosis. The localisation of urokinase‐type plasminogen activator receptor (uPAR) was determined in 66 patients; 60 with adenocarcinomas and six cases with Barrett's oes...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cancer 2012-08, Vol.131 (3), p.558-569
Hauptverfasser: Lærum, Ole Didrik, Ovrebo, Kjell, Skarstein, Arne, Christensen, Ib Jarle, Alpízar-Alpízar, Warner, Helgeland, Lars, Danø, Keld, Nielsen, Boye Schnack, Illemann, Martin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 569
container_issue 3
container_start_page 558
container_title International journal of cancer
container_volume 131
creator Lærum, Ole Didrik
Ovrebo, Kjell
Skarstein, Arne
Christensen, Ib Jarle
Alpízar-Alpízar, Warner
Helgeland, Lars
Danø, Keld
Nielsen, Boye Schnack
Illemann, Martin
description Adenocarcinomas of lower oesophagus, gastro‐oesophageal junction and cardia in humans are highly invasive tumours with poor prognosis. The localisation of urokinase‐type plasminogen activator receptor (uPAR) was determined in 66 patients; 60 with adenocarcinomas and six cases with Barrett's oesophagus. uPAR was expressed in nearly all cases of invasive adenocarcinomas by populations of cancer cells, macrophages and myofibroblasts at both the invasion front and the tumour core. In areas with high‐grade dysplasia or with Barrett's metaplasia adjacent to the tumour tissue, no uPAR‐immunoreactivity was found. High local expression of uPAR, therefore, appears to be a characteristic marker for invasive behaviour in this tumour, suggesting that uPAR's contribution to matrix degradation during invasive growth is a late event in carcinogenesis. Using a scoring system for semiquantitative estimation of uPAR‐positivity on immmunohistochemically stained specimens, a significant association was found between poor overall survival and high uPAR‐score for cancer cells in the tumour core and for macrophages peripherally at the tumour invasion zone. In multivariate analysis, these two uPAR‐scores were confirmed as highly significant prognostic parameters independent of Tumour, Node, Metastasis (TNM)‐stage and World Health Organization (WHO) classification. The proteolytic action of these malignant and nonmalignant accessory cells thus seemed to follow two main patterns: one dominated by uPAR positive cancer cells and one by uPAR‐positive macrophages. Scoring of uPAR‐positivity might be a useful parameter for onset of invasion and prognosis in these adenocarcinomas.
doi_str_mv 10.1002/ijc.26382
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3118798665</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3073977261</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4842-ae155a149e59ceebe63ca0acb04f1fe66bc5ac12ea1e883af9c2103a5a47e6e93</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS0EokvhwBdAllAPSKS149hJjtWK_tMCBUHhZk2cya6XJF7shHZP_ep42d1ygtNIM7_3njSPkJecHXPG0hO7NMepEkX6iEw4K_OEpVw-JpN4Y0nOhTogz0JYMsa5ZNlTcpDyQimZFRNyf-3dvHfBBmp7CjX2zoA3tncdBOoa2rpb9NRhcKsFzMfwls4hDN4l-xVCS5djbwbrokFf06ivLVD8Be0IA9a0WtPx-vRzYrtu7N3ChsGZBXZx-vVz8qSBNuCL3TwkX8_efZleJLOP55fT01lisiJLE0AuJfCsRFkaxAqVMMDAVCxreINKVUaC4SkCx6IQ0JQm5UyAhCxHhaU4JK-3vivvfo4YBr10o-9jpBacF3m5ecj_KJ6JCJZ5tqHebCnjXQgeG73ytgO_1pzpTSE6FqL_FBLZVzvHseqwfiD3DUTgaAdAMNA2Hnpjw19OMa5kySJ3suVubYvrfyfqy6vpPjrZKuKj8e5BAf6HVrnIpf724VzfXL0_-z67uNGfxG_tZ7OL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1433119745</pqid></control><display><type>article</type><title>Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via Wiley Online Library</source><creator>Lærum, Ole Didrik ; Ovrebo, Kjell ; Skarstein, Arne ; Christensen, Ib Jarle ; Alpízar-Alpízar, Warner ; Helgeland, Lars ; Danø, Keld ; Nielsen, Boye Schnack ; Illemann, Martin</creator><creatorcontrib>Lærum, Ole Didrik ; Ovrebo, Kjell ; Skarstein, Arne ; Christensen, Ib Jarle ; Alpízar-Alpízar, Warner ; Helgeland, Lars ; Danø, Keld ; Nielsen, Boye Schnack ; Illemann, Martin</creatorcontrib><description>Adenocarcinomas of lower oesophagus, gastro‐oesophageal junction and cardia in humans are highly invasive tumours with poor prognosis. The localisation of urokinase‐type plasminogen activator receptor (uPAR) was determined in 66 patients; 60 with adenocarcinomas and six cases with Barrett's oesophagus. uPAR was expressed in nearly all cases of invasive adenocarcinomas by populations of cancer cells, macrophages and myofibroblasts at both the invasion front and the tumour core. In areas with high‐grade dysplasia or with Barrett's metaplasia adjacent to the tumour tissue, no uPAR‐immunoreactivity was found. High local expression of uPAR, therefore, appears to be a characteristic marker for invasive behaviour in this tumour, suggesting that uPAR's contribution to matrix degradation during invasive growth is a late event in carcinogenesis. Using a scoring system for semiquantitative estimation of uPAR‐positivity on immmunohistochemically stained specimens, a significant association was found between poor overall survival and high uPAR‐score for cancer cells in the tumour core and for macrophages peripherally at the tumour invasion zone. In multivariate analysis, these two uPAR‐scores were confirmed as highly significant prognostic parameters independent of Tumour, Node, Metastasis (TNM)‐stage and World Health Organization (WHO) classification. The proteolytic action of these malignant and nonmalignant accessory cells thus seemed to follow two main patterns: one dominated by uPAR positive cancer cells and one by uPAR‐positive macrophages. Scoring of uPAR‐positivity might be a useful parameter for onset of invasion and prognosis in these adenocarcinomas.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.26382</identifier><identifier>PMID: 21866548</identifier><identifier>CODEN: IJCNAW</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>adenocarcinoma ; Adenocarcinoma - chemistry ; Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adenocarcinoma - surgery ; Adult ; Aged ; Aged, 80 and over ; Antigen-presenting cells ; Barrett Esophagus - metabolism ; Barrett Esophagus - pathology ; Barrett's esophagus ; Barrett's metaplasia ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; Cancer ; Carcinogenesis ; Cardia ; Cells ; Esophageal cancer ; Esophageal Neoplasms - chemistry ; Esophageal Neoplasms - mortality ; Esophageal Neoplasms - pathology ; Esophageal Neoplasms - surgery ; Esophagogastric Junction ; Esophagus ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Immunoenzyme Techniques ; Immunohistochemistry ; invasion ; Invasiveness ; Macrophages ; Macrophages - chemistry ; Male ; Medical prognosis ; Medical research ; Medical sciences ; Metaplasia ; Metastases ; Middle Aged ; Multivariate analysis ; Myofibroblasts - chemistry ; Neoplasm Invasiveness ; oesophagus ; Prognosis ; Proteolysis ; Receptors, Urokinase Plasminogen Activator - analysis ; Receptors, Urokinase Plasminogen Activator - immunology ; Stomach Neoplasms - chemistry ; Stomach Neoplasms - mortality ; Stomach Neoplasms - pathology ; Stomach Neoplasms - surgery ; Survival Rate ; Tumors ; U-Plasminogen activator ; uPAR</subject><ispartof>International journal of cancer, 2012-08, Vol.131 (3), p.558-569</ispartof><rights>Copyright © 2011 UICC</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 UICC.</rights><rights>Copyright Wiley Subscription Services, Inc. Aug 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4842-ae155a149e59ceebe63ca0acb04f1fe66bc5ac12ea1e883af9c2103a5a47e6e93</citedby><cites>FETCH-LOGICAL-c4842-ae155a149e59ceebe63ca0acb04f1fe66bc5ac12ea1e883af9c2103a5a47e6e93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijc.26382$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijc.26382$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26016590$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21866548$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lærum, Ole Didrik</creatorcontrib><creatorcontrib>Ovrebo, Kjell</creatorcontrib><creatorcontrib>Skarstein, Arne</creatorcontrib><creatorcontrib>Christensen, Ib Jarle</creatorcontrib><creatorcontrib>Alpízar-Alpízar, Warner</creatorcontrib><creatorcontrib>Helgeland, Lars</creatorcontrib><creatorcontrib>Danø, Keld</creatorcontrib><creatorcontrib>Nielsen, Boye Schnack</creatorcontrib><creatorcontrib>Illemann, Martin</creatorcontrib><title>Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry</title><title>International journal of cancer</title><addtitle>Int. J. Cancer</addtitle><description>Adenocarcinomas of lower oesophagus, gastro‐oesophageal junction and cardia in humans are highly invasive tumours with poor prognosis. The localisation of urokinase‐type plasminogen activator receptor (uPAR) was determined in 66 patients; 60 with adenocarcinomas and six cases with Barrett's oesophagus. uPAR was expressed in nearly all cases of invasive adenocarcinomas by populations of cancer cells, macrophages and myofibroblasts at both the invasion front and the tumour core. In areas with high‐grade dysplasia or with Barrett's metaplasia adjacent to the tumour tissue, no uPAR‐immunoreactivity was found. High local expression of uPAR, therefore, appears to be a characteristic marker for invasive behaviour in this tumour, suggesting that uPAR's contribution to matrix degradation during invasive growth is a late event in carcinogenesis. Using a scoring system for semiquantitative estimation of uPAR‐positivity on immmunohistochemically stained specimens, a significant association was found between poor overall survival and high uPAR‐score for cancer cells in the tumour core and for macrophages peripherally at the tumour invasion zone. In multivariate analysis, these two uPAR‐scores were confirmed as highly significant prognostic parameters independent of Tumour, Node, Metastasis (TNM)‐stage and World Health Organization (WHO) classification. The proteolytic action of these malignant and nonmalignant accessory cells thus seemed to follow two main patterns: one dominated by uPAR positive cancer cells and one by uPAR‐positive macrophages. Scoring of uPAR‐positivity might be a useful parameter for onset of invasion and prognosis in these adenocarcinomas.</description><subject>adenocarcinoma</subject><subject>Adenocarcinoma - chemistry</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antigen-presenting cells</subject><subject>Barrett Esophagus - metabolism</subject><subject>Barrett Esophagus - pathology</subject><subject>Barrett's esophagus</subject><subject>Barrett's metaplasia</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Cancer</subject><subject>Carcinogenesis</subject><subject>Cardia</subject><subject>Cells</subject><subject>Esophageal cancer</subject><subject>Esophageal Neoplasms - chemistry</subject><subject>Esophageal Neoplasms - mortality</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Esophageal Neoplasms - surgery</subject><subject>Esophagogastric Junction</subject><subject>Esophagus</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Immunohistochemistry</subject><subject>invasion</subject><subject>Invasiveness</subject><subject>Macrophages</subject><subject>Macrophages - chemistry</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Metaplasia</subject><subject>Metastases</subject><subject>Middle Aged</subject><subject>Multivariate analysis</subject><subject>Myofibroblasts - chemistry</subject><subject>Neoplasm Invasiveness</subject><subject>oesophagus</subject><subject>Prognosis</subject><subject>Proteolysis</subject><subject>Receptors, Urokinase Plasminogen Activator - analysis</subject><subject>Receptors, Urokinase Plasminogen Activator - immunology</subject><subject>Stomach Neoplasms - chemistry</subject><subject>Stomach Neoplasms - mortality</subject><subject>Stomach Neoplasms - pathology</subject><subject>Stomach Neoplasms - surgery</subject><subject>Survival Rate</subject><subject>Tumors</subject><subject>U-Plasminogen activator</subject><subject>uPAR</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxS0EokvhwBdAllAPSKS149hJjtWK_tMCBUHhZk2cya6XJF7shHZP_ep42d1ygtNIM7_3njSPkJecHXPG0hO7NMepEkX6iEw4K_OEpVw-JpN4Y0nOhTogz0JYMsa5ZNlTcpDyQimZFRNyf-3dvHfBBmp7CjX2zoA3tncdBOoa2rpb9NRhcKsFzMfwls4hDN4l-xVCS5djbwbrokFf06ivLVD8Be0IA9a0WtPx-vRzYrtu7N3ChsGZBXZx-vVz8qSBNuCL3TwkX8_efZleJLOP55fT01lisiJLE0AuJfCsRFkaxAqVMMDAVCxreINKVUaC4SkCx6IQ0JQm5UyAhCxHhaU4JK-3vivvfo4YBr10o-9jpBacF3m5ecj_KJ6JCJZ5tqHebCnjXQgeG73ytgO_1pzpTSE6FqL_FBLZVzvHseqwfiD3DUTgaAdAMNA2Hnpjw19OMa5kySJ3suVubYvrfyfqy6vpPjrZKuKj8e5BAf6HVrnIpf724VzfXL0_-z67uNGfxG_tZ7OL</recordid><startdate>20120801</startdate><enddate>20120801</enddate><creator>Lærum, Ole Didrik</creator><creator>Ovrebo, Kjell</creator><creator>Skarstein, Arne</creator><creator>Christensen, Ib Jarle</creator><creator>Alpízar-Alpízar, Warner</creator><creator>Helgeland, Lars</creator><creator>Danø, Keld</creator><creator>Nielsen, Boye Schnack</creator><creator>Illemann, Martin</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Blackwell</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope></search><sort><creationdate>20120801</creationdate><title>Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry</title><author>Lærum, Ole Didrik ; Ovrebo, Kjell ; Skarstein, Arne ; Christensen, Ib Jarle ; Alpízar-Alpízar, Warner ; Helgeland, Lars ; Danø, Keld ; Nielsen, Boye Schnack ; Illemann, Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4842-ae155a149e59ceebe63ca0acb04f1fe66bc5ac12ea1e883af9c2103a5a47e6e93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>adenocarcinoma</topic><topic>Adenocarcinoma - chemistry</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antigen-presenting cells</topic><topic>Barrett Esophagus - metabolism</topic><topic>Barrett Esophagus - pathology</topic><topic>Barrett's esophagus</topic><topic>Barrett's metaplasia</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Cancer</topic><topic>Carcinogenesis</topic><topic>Cardia</topic><topic>Cells</topic><topic>Esophageal cancer</topic><topic>Esophageal Neoplasms - chemistry</topic><topic>Esophageal Neoplasms - mortality</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Esophageal Neoplasms - surgery</topic><topic>Esophagogastric Junction</topic><topic>Esophagus</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Immunohistochemistry</topic><topic>invasion</topic><topic>Invasiveness</topic><topic>Macrophages</topic><topic>Macrophages - chemistry</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Metaplasia</topic><topic>Metastases</topic><topic>Middle Aged</topic><topic>Multivariate analysis</topic><topic>Myofibroblasts - chemistry</topic><topic>Neoplasm Invasiveness</topic><topic>oesophagus</topic><topic>Prognosis</topic><topic>Proteolysis</topic><topic>Receptors, Urokinase Plasminogen Activator - analysis</topic><topic>Receptors, Urokinase Plasminogen Activator - immunology</topic><topic>Stomach Neoplasms - chemistry</topic><topic>Stomach Neoplasms - mortality</topic><topic>Stomach Neoplasms - pathology</topic><topic>Stomach Neoplasms - surgery</topic><topic>Survival Rate</topic><topic>Tumors</topic><topic>U-Plasminogen activator</topic><topic>uPAR</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lærum, Ole Didrik</creatorcontrib><creatorcontrib>Ovrebo, Kjell</creatorcontrib><creatorcontrib>Skarstein, Arne</creatorcontrib><creatorcontrib>Christensen, Ib Jarle</creatorcontrib><creatorcontrib>Alpízar-Alpízar, Warner</creatorcontrib><creatorcontrib>Helgeland, Lars</creatorcontrib><creatorcontrib>Danø, Keld</creatorcontrib><creatorcontrib>Nielsen, Boye Schnack</creatorcontrib><creatorcontrib>Illemann, Martin</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lærum, Ole Didrik</au><au>Ovrebo, Kjell</au><au>Skarstein, Arne</au><au>Christensen, Ib Jarle</au><au>Alpízar-Alpízar, Warner</au><au>Helgeland, Lars</au><au>Danø, Keld</au><au>Nielsen, Boye Schnack</au><au>Illemann, Martin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int. J. Cancer</addtitle><date>2012-08-01</date><risdate>2012</risdate><volume>131</volume><issue>3</issue><spage>558</spage><epage>569</epage><pages>558-569</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><coden>IJCNAW</coden><abstract>Adenocarcinomas of lower oesophagus, gastro‐oesophageal junction and cardia in humans are highly invasive tumours with poor prognosis. The localisation of urokinase‐type plasminogen activator receptor (uPAR) was determined in 66 patients; 60 with adenocarcinomas and six cases with Barrett's oesophagus. uPAR was expressed in nearly all cases of invasive adenocarcinomas by populations of cancer cells, macrophages and myofibroblasts at both the invasion front and the tumour core. In areas with high‐grade dysplasia or with Barrett's metaplasia adjacent to the tumour tissue, no uPAR‐immunoreactivity was found. High local expression of uPAR, therefore, appears to be a characteristic marker for invasive behaviour in this tumour, suggesting that uPAR's contribution to matrix degradation during invasive growth is a late event in carcinogenesis. Using a scoring system for semiquantitative estimation of uPAR‐positivity on immmunohistochemically stained specimens, a significant association was found between poor overall survival and high uPAR‐score for cancer cells in the tumour core and for macrophages peripherally at the tumour invasion zone. In multivariate analysis, these two uPAR‐scores were confirmed as highly significant prognostic parameters independent of Tumour, Node, Metastasis (TNM)‐stage and World Health Organization (WHO) classification. The proteolytic action of these malignant and nonmalignant accessory cells thus seemed to follow two main patterns: one dominated by uPAR positive cancer cells and one by uPAR‐positive macrophages. Scoring of uPAR‐positivity might be a useful parameter for onset of invasion and prognosis in these adenocarcinomas.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>21866548</pmid><doi>10.1002/ijc.26382</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0020-7136
ispartof International journal of cancer, 2012-08, Vol.131 (3), p.558-569
issn 0020-7136
1097-0215
language eng
recordid cdi_proquest_journals_3118798665
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via Wiley Online Library
subjects adenocarcinoma
Adenocarcinoma - chemistry
Adenocarcinoma - mortality
Adenocarcinoma - pathology
Adenocarcinoma - surgery
Adult
Aged
Aged, 80 and over
Antigen-presenting cells
Barrett Esophagus - metabolism
Barrett Esophagus - pathology
Barrett's esophagus
Barrett's metaplasia
Biological and medical sciences
Biomarkers, Tumor - analysis
Cancer
Carcinogenesis
Cardia
Cells
Esophageal cancer
Esophageal Neoplasms - chemistry
Esophageal Neoplasms - mortality
Esophageal Neoplasms - pathology
Esophageal Neoplasms - surgery
Esophagogastric Junction
Esophagus
Female
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Immunoenzyme Techniques
Immunohistochemistry
invasion
Invasiveness
Macrophages
Macrophages - chemistry
Male
Medical prognosis
Medical research
Medical sciences
Metaplasia
Metastases
Middle Aged
Multivariate analysis
Myofibroblasts - chemistry
Neoplasm Invasiveness
oesophagus
Prognosis
Proteolysis
Receptors, Urokinase Plasminogen Activator - analysis
Receptors, Urokinase Plasminogen Activator - immunology
Stomach Neoplasms - chemistry
Stomach Neoplasms - mortality
Stomach Neoplasms - pathology
Stomach Neoplasms - surgery
Survival Rate
Tumors
U-Plasminogen activator
uPAR
title Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T13%3A09%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognosis%20in%20adenocarcinomas%20of%20lower%20oesophagus,%20gastro-oesophageal%20junction%20and%20cardia%20evaluated%20by%20uPAR-immunohistochemistry&rft.jtitle=International%20journal%20of%20cancer&rft.au=L%C3%A6rum,%20Ole%20Didrik&rft.date=2012-08-01&rft.volume=131&rft.issue=3&rft.spage=558&rft.epage=569&rft.pages=558-569&rft.issn=0020-7136&rft.eissn=1097-0215&rft.coden=IJCNAW&rft_id=info:doi/10.1002/ijc.26382&rft_dat=%3Cproquest_cross%3E3073977261%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1433119745&rft_id=info:pmid/21866548&rfr_iscdi=true